Evidence map›Paper›PMID 37552278›Full record

ArticleJournal of neurology2023

Combined measure of salivary alpha-synuclein species as diagnostic biomarker for Parkinson's disease.

Fabrizio Angius, Ignazia Mocci, Tommaso Ercoli, Francesco Loy, Laura Fadda, Maria Francesca Palmas, Giada Cannas, Aldo Manzin, Giovanni Defazio, Anna R Carta

Abstract read
In one paragraph

Article in Journal of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Fabrizio AngiusDepartment of Biomedical Sciences, University of Cagliari, Cagliari, Italy.ORCID http://orcid.org/0000-0001-6613-603X
Ignazia Mocci *CNR Institute of Translational Pharmacology, Unit of Cagliari, Cagliari, Italy.ORCID http://orcid.org/0000-0003-3062-751X
Tommaso Ercoli *Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.ORCID http://orcid.org/0000-0002-3260-1754
Francesco LoyDepartment of Biomedical Sciences, University of Cagliari, Cagliari, Italy.ORCID http://orcid.org/0000-0002-6600-3883
Laura FaddaDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Maria Francesca PalmasDepartment of Biomedical Sciences, University of Cagliari, Cagliari, Italy.ORCID http://orcid.org/0000-0001-7449-9498
Giada CannasDepartment of Biomedical Sciences, University of Cagliari, Cagliari, Italy.
Aldo ManzinDepartment of Biomedical Sciences, University of Cagliari, Cagliari, Italy.ORCID http://orcid.org/0000-0003-2961-3428
Giovanni DefazioDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. giovanni.defazio@uniba.it.ORCID http://orcid.org/0000-0002-8221-439X
Anna R CartaDepartment of Biomedical Sciences, University of Cagliari, Cagliari, Italy.ORCID http://orcid.org/0000-0003-3104-9010

Funding

Regione Autonoma della Sardegna RASSR08834
6 · The paper itself

Abstract

Parkinson's disease (PD) diagnosis is still vulnerable to bias, and a definitive diagnosis often relies on post-mortem neuropathological diagnosis. In this regard, alpha-synuclein (αsyn)-specific in vivo biomarkers remain a critical unmet need, based on its relevance in the neuropathology. Specifically, content changes in αsyn species such as total (tot-αsyn), oligomeric (o-αsyn), and phosphorylated (p-αsyn) within the cerebrospinal fluid (CSF) and peripheral fluids (i.e., blood and saliva) have been proposed as PD biomarkers possibly reflecting the neuropathological outcome. Here, we measured the p-αsyn levels in the saliva from 15 PD patients along with tot-αsyn, o-αsyn and their ratios, and compared the results with those from 23 healthy subjects (HS), matched per age and sex. We also calculated the optimal cutoff values for different αsyn species to provide information about their capability to discriminate PD from HS. We found that p-αsyn was the most abundant alpha-synuclein species in the saliva. While p-αsyn concentration did not differ between PD and HS when adjusted for total salivary proteins, the ratio p-αsyn/tot-αsyn was largely lower in PD patients than in HS. Moreover, the concentration of o-αsyn was increased in the saliva of PD patients, and tot-αsyn did not differ between PD and HS. The ROC curves indicated that no single αsyn form or ratio could provide an accurate diagnosis of PD. On the other hand, the ratio of different items, namely p-αsyn/tot-αsyn and o-αsyn, yielded more satisfactory diagnostic accuracy, suggesting that the combined measure of different species in the saliva may show more promises as a diagnostic means for PD.

Indexed as

Parkinson Diseasealpha-SynucleinBiomarkersHumansROC Curvealpha-SynucleinBiomarkersAlpha-synucleinBiomarkersParkinson’s diseaseSaliva

Identifiers

PMID37552278
PMCPMC10576686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.